Pr Pierre Feugier has just presented orally at the ASH (American Society of Hematology) which takes place in Atlanta between 08th and 12th of December 2017 the first results of the ICLL07 GAI trial. This trial included patients with CLL disease requiring a 1st line of treatment. The first part of treatment consists of combination of Obinutuzumab (new generation anti-CD20 antibody) with Ibrutinib (BTK inhibitor). After evaluation of Minimal Residual Disease in bone marrow at months 9, patients with « low » MRD continue to be treated by Ibrutinb only. The others receive a second part of treatment with Fludarabine-Cyclophosphamide-Obinutuzumab (4 cycles) and Ibrutinib. A second evaluation is planned at months 16 months.
Stay informed by discovering below the news published by the FILO Group.
New for IMBRUVICA® (ibrutinib), a Bruton tyrosine kinase inhibitor (BTK) already widely used in CLL and Mantle Cell Lymphoma.
It has recently been granted marketing authorization (MA) for the treatment of adult patients with Waldenström macroglobulinemia (WM) who have received at least one prior treatment, or as a first-line treatment in patients for whom chemo-immunotherapy is not appropriate.
And more, it is now available in town pharmacies!
Caroline Dartigeas presented the results of the CLL2007SA test for patients over 65 years of age without too much comorbidity (CIRS <6), with symptomatic CLL2007SA.
After 4 cycles of Fludarabine-Cyclophosphamide and 6 perfusions of Rituximab, 409 responders were randomized between maintenance by bi-monthly infusions of Rituximab for 2 years and a therapeutic abstention.
Maintenance increased the PFS (progression-free survival) of patients admitted to the maintenance arm, even though there were some biological factors known to be of poorer prognosis (del 11q and non-mutated IGVH status). On the other hand, OS (overall survival) has not been improved.
Since 15 February 2017, we can now prescribe Venclyxto® (Vénétoclax) as monotherapy:
- For the treatment of CLL in the presence of 17p deletion or TP53 mutation in ineligible patients or in failure of an antigenic B-cell receptor inhibitor.
- For the treatment of CLL in the absence of 17p deletion or TP53 mutation in adult patients who have failed both chemo-immunotherapy and an inhibitor of the B-cell antigen receptor